Studies on mice lacking the peroxisome proliferator-activated receptor (PPAR) suggest that PPAR ligands reduce lipid accumulation in foamy macrophages, and may target other receptors. These findings warrant an in-depth investigation into the gene regulatory mechanisms of PPAR ligands, which are currently being developed as drugs to treat atherosclerosis and diabetes. (pages 41–47)
This is a preview of subscription content, access via your institution
Access options
Subscribe to this journal
Receive 12 print issues and online access
$209.00 per year
only $17.42 per issue
Buy this article
- Purchase on Springer Link
- Instant access to full article PDF
Prices may be subject to local taxes which are calculated during checkout
References
Rangwala, S.M. & Lazar, M.A. Transcriptional control of adipogenesis. Ann. Rev. Nutr. 8, 535–559 (2000).
Ricote, M., Li, A.C., Willson, T.M., Kelly, C.J. & Glass, C.K. The peroxisome proliferator-activated receptor-γ is a negative regulator of macrophage activation. Nature 391, 79–82 (1998).
Tontonoz, P., Nagy, L., Alvarez, J.G., Thomazy, V.A. & Evans, R.M. PPAR-γ promotes monocyte/macrophage differentiation and uptake of oxidized LDL. Cell 93, 241–252 (1998).
Moore, K.J. et al. Role of PPAR-γ in macrophage differentiation and cholesterol uptake. Nature Med. 7, 41–47 (2000).
Chawla, A. et al. Generation of PPAR-γ null macrophages reveals role in regulation of gene expression linked to lipid metabolism but not inflammation. Nature Med. 7, 48–52 (2000).
Chinetti, G. et al. PPAR-α and PPAR-γ activators induce cholesterol removal from human macrophage foam cells through stimulation of the ABCA1 pathway. Nature Med. 7, 53–58 (2000).
Olefsky, J.M. Treatment of insulin resistance with peroxisome proliferator-activated receptor-γ agonists. J. Clin. Invest. 106, 467–472 (2000).
Seed, B. PPAR-γ and colorectal carcinoma: conflicts in a nuclear family. Nature Med. 4, 1004–10005 (1998).
Nagy, L., Tontonoz, P., Alvarez, J.G., Chen, H. & Evans, R.M. Oxidized LDL regulates macrophage gene expression through activation of PPAR-γ. Cell 93, 229–240 (1998).
Jiang, C., Ting, A.T. & Seed, B. PPAR-γ agonists inhibit production of monocyte inflammatory cytokines. Nature 391, 82–86 (1998).
Rosen, E.D. & Spiegelman, B.M. Peroxisome proliferator-activated receptor-γ ligands and atherosclerosis: ending the heartache. J. Clin. Invest. 106, 629–631 (2000).
Rossi, A. et al. Anti-inflammatory cyclopentenone prostaglandins are direct inhibitors of IκB kinase. Nature 403, 103–108 (2000).
Author information
Authors and Affiliations
Rights and permissions
About this article
Cite this article
Lazar, M. Progress in cardiovascular biology: PPAR for the course. Nat Med 7, 23–24 (2001). https://doi.org/10.1038/83301
Issue Date:
DOI: https://doi.org/10.1038/83301
This article is cited by
-
Evaluating the effect of cinnamon and rosuvastatin, on the formation of foam cells in macrophages co-cultured with platelets
Advances in Traditional Medicine (2022)
-
Emerging role of adipose tissue hypoxia in obesity and insulin resistance
International Journal of Obesity (2009)
-
Importance of blood cellular genomic profile in coronary heart disease
Journal of Biomedical Science (2006)